Actively Recruiting

Phase 2
Age: 50Years - 89Years
All Genders
NCT06460038

Tenapanor in Synucleinopathy-Related Constipation

Led by Cedar Valley Digestive Health Center · Updated on 2025-02-10

30

Participants Needed

1

Research Sites

112 weeks

Total Duration

On this page

Sponsors

C

Cedar Valley Digestive Health Center

Lead Sponsor

A

Ardelyx

Collaborating Sponsor

AI-Summary

What this Trial Is About

Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

CONDITIONS

Official Title

Tenapanor in Synucleinopathy-Related Constipation

Who Can Participate

Age: 50Years - 89Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 50 to 89 years
  • Diagnosis of Parkinson's disease within Hoehn and Yahr stages 1 to 3, confirmed by a neurologist using International Parkinson and Movement Disorder Society criteria
  • Average weekly stool frequency of 5 or fewer spontaneous bowel movements and 2 or fewer complete spontaneous bowel movements over the past 6 months, verified during a 2-week screening period
  • Stool consistency of 3 or less on the Bristol Stool Form Scale, verified during a 2-week screening period
  • Agreement to use contraception, if applicable
Not Eligible

You will not qualify if you...

  • Functional diarrhea or irritable bowel syndrome with diarrhea or mixed type based on Rome IV Criteria
  • Symptomatic structural gastrointestinal abnormalities or inflammatory bowel disease
  • Significant liver dysfunction (ALT or AST 2.5 times or more above normal) or kidney dysfunction (serum creatinine greater than 2 mg/dl)
  • Pregnancy or breastfeeding
  • Diagnosis of primary dyssynergic defecation confirmed by anorectal manometry

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cedar Valley Digestive Health Center

Waterloo, Iowa, United States, 50701

Actively Recruiting

Loading map...

Research Team

R

Richard A. Manfready, MD, AM, FACP

CONTACT

H

Harichandana Punukula, PharmD, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here